Drug Information

Drug General Information
Drug ID
D07QMC
Former ID
DNC003626
Drug Name
3-Benzimidazol-2-ylhydroquinolin-2-one
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529891]
Formula
C16H11N3O
Canonical SMILES
C1=CC=C2C(=C1)NC(=C3C=C4C=CC=CC4=NC3=O)N2
InChI
1S/C16H11N3O/c20-16-11(9-10-5-1-2-6-12(10)19-16)15-17-13-7-3-4-8-14(13)18-15/h1-9,17-18H
InChIKey
VAAMBTAFTGILMX-UHFFFAOYSA-N
PubChem Compound ID
5329370
Target and Pathway
Target(s) Vascular endothelial growth factor receptor 2 Target Info Inhibitor [529891]
Beta platelet-derived growth factor receptor Target Info Inhibitor [529891]
Basic fibroblast growth factor receptor 1 Target Info Inhibitor [529891]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04010:MAPK signaling pathway
Calcium signaling pathway
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
Pathways in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancerhsa04010:MAPK signaling pathway
Adherens junction
Signaling pathways regulating pluripotency of stem cells
Proteoglycans in cancer
NetPath Pathway IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathwayP00005:Angiogenesis
PDGF signaling pathwayP00005:Angiogenesis
FGF signaling pathway
Pathway Interaction Database HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkptp1bpathway:Signaling events mediated by PTP1B
S1P3 pathway
Nectin adhesion pathway
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PDGFR-beta signaling pathway
Validated targets of C-MYC transcriptional repression
PDGF receptor signaling networkglypican_1pathway:Glypican 1 network
Syndecan-4-mediated signaling events
N-cadherin signaling events
FGF signaling pathway
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascade
WikiPathways Focal Adhesion
Nifedipine Activity
Cardiac Progenitor Differentiation
Signaling by VEGF
AngiogenesisWP51:Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Osteoblast Signaling
PIP3 activates AKT signaling
PDGF Pathway
Signaling Pathways in Glioblastoma
Signaling by PDGFWP51:Regulation of Actin Cytoskeleton
Endochondral Ossification
Mesodermal Commitment Pathway
Hair Follicle Development: Induction (Part 1 of 3)
Integrated Pancreatic Cancer Pathway
Neural Crest Differentiation
Signaling by FGFR
References
Ref 529891J Med Chem. 2009 Jan 22;52(2):278-92.Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
Ref 529891J Med Chem. 2009 Jan 22;52(2):278-92.Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.